Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Ask almost any CFA® charterholder, and they’ll tell you: Level II is where things get serious. It’s often considered the hardest of the three exams, and the prep course that got you through Level I ...

The level cap in The Outer Worlds 2 is the highest level your character can reach. As you defeat enemies and complete quests, you’ll slowly get closer to this maximum level, but it’ll take a while — ...

There are several Skills you can invest in as you level up throughout The Outer Worlds 2, each bolstering your abilities in specific areas. But what is the max level cap for each/any Skill? This guide ...

Vash Level 2 has been garnering significant attention ever since it hit theaters, and the responses from critics and audiences are also amazing. Vash Level 2 is a 2025 Indian Gujarati-language ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the ...